cbdMD, Inc.

YCBD Healthcare Drug Manufacturers Specialty & Generic

cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS grew 47.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$4.0M
P/E
41.2×
Fwd P/E
−3.8×
Dividend yield
—
F-score
6/9
Altman Z
−21.65
Beneish M
−2.51
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 78.82
P/S ratio
0.25 0.64 0.39 0.34
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(20.21) (14.96) (10.70) (16.09)
P/B ratio
0.67 1.35 0.83 0.87
EV/Sales
0.26 0.59 0.38 0.35
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(2.94) (5.07) (2.75) (2.98)
Current Ratio
2.05 2.94 2.82 2.50
Net Debt/EBITDA
8.93 (26.00) 6.98 3.07
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(300.12%) (141.59%) (12.36%) 1.27%
Free Cash Flow Yield
(35.06%) (18.11%) (35.26%) (34.86%)
Free Cash Flow per Share
(0.06) (0.11) (0.07) (0.04)
Book value per Share
1.80 1.00 0.89 0.77
Free Cash Flow
(0.24) (0.98) (0.73) (0.46)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates